Propanc Biopharma (PPCB) Total Current Liabilities (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Total Current Liabilities of $3.6 million for Q4 2025, down 12.78% year-over-year from $4.2 million in Q4 2024, and up 1.44% quarter-over-quarter from $3.6 million in Q3 2025.
Propanc Biopharma (PPCB) Total Current Liabilities (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Total Current Liabilities for 15 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities fell 12.78% year-over-year to $3.6 million; the TTM figure through Dec 2025 stood at $3.6 million (down 12.78% YoY), while the FY2025 annual figure was $5.6 million, up 47.08% from the prior year.
- Total Current Liabilities improved to $3.6 million in Q4 2025 per PPCB's latest filing, from $3.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $5.6 million in Q2 2025 and bottomed at $2.4 million in Q3 2021.
- Historically, Total Current Liabilities has averaged $3.5 million across 5 years, with a median of $3.1 million in 2023.
- Annual changes were most pronounced in 2021 — Total Current Liabilities plunged 38.01% — and 2025, when it jumped 47.08%.
- Propanc Biopharma's Total Current Liabilities stood at $3.0 million in 2021, then dropped by 1.57% to $3.0 million in 2022, then gained by 25.72% to $3.8 million in 2023, then advanced by 10.44% to $4.2 million in 2024, then declined by 12.78% to $3.6 million in 2025.
- Business Quant data shows PPCB's Total Current Liabilities at $3.6 million in Q4 2025, $3.6 million in Q3 2025, and $5.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 3.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.62 Mn |
| Sep 30, 2025 | 3.57 Mn |
| Jun 30, 2025 | 5.58 Mn |
| Mar 31, 2025 | 4.34 Mn |
| Dec 31, 2024 | 4.15 Mn |
| Sep 30, 2024 | 4.10 Mn |
| Jun 30, 2024 | 3.79 Mn |
| Mar 31, 2024 | 3.69 Mn |
| Dec 31, 2023 | 3.76 Mn |
| Sep 30, 2023 | 3.13 Mn |
| Jun 30, 2023 | 3.16 Mn |
| Mar 31, 2023 | 3.06 Mn |
| Dec 31, 2022 | 2.99 Mn |
| Sep 30, 2022 | 2.82 Mn |
| Jun 30, 2022 | 3.06 Mn |
| Mar 31, 2022 | 3.12 Mn |
| Dec 31, 2021 | 3.04 Mn |
| Sep 30, 2021 | 2.37 Mn |
| Jun 30, 2021 | 3.08 Mn |
| Mar 31, 2021 | 3.03 Mn |